83

3SBio IncFRA 3SBio Stock Report

Last reporting period 30 Jun, 2024

Updated 13 Nov, 2024

Last price

Market cap $B

1.825

Small

Exchange

XFRA - Deutsche Boerse AG

83B.F Stock Analysis

83

Uncovered

3SBio Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

69/100

Moderate score

Market cap $B

1.825

Dividend yield

3.81 %

Shares outstanding

2 436.68 B

3SBio, Inc. operates as an investment holding company, which engages in the development, production, marketing, and sale of biopharmaceutical products. The company is headquartered in Shenyang, Liaoning and currently employs 5,160 full-time employees. The company went IPO on 2015-06-11. The Company’s main products include recombinant human thrombopoietin (rhTPO) products, tumor necrosis factor (TNF)αinhibitor products and recombinant human erythropoietin (rhEPO) products. The products are sold under the name of TPIAO, Yisaipu, EPIAO and SEPO. The firm distributes its products within the domestic market and to overseas markets, including Sri Lanka, Dominican Republic and Thailand. The Company’s subsidiaries include Collected Mind Limited, Hongkong Sansheng Medical Limited and Shenyang Sunshine Pharmaceutical Co., Ltd.. Through its subsidiaries, the Company is engaged in project management and consultation.

View Section: Eyestock Rating